# A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C

> **NCT00118768** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 175 (—)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** valopicitabine
- **DRUG:** Pegylated Interferon Alfa

## Key facts

- **NCT ID:** NCT00118768
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 175 (—)
- **Last updated:** 2009-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00118768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00118768, "A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00118768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*